The global Hedgehog Pathway Inhibitors market is expected to reach USD 961.7 million by the year 2026, at a CAGR of 10.3%. The study covers drivers, obstruction, and future revenue opportunities of the Hedgehog pathway inhibitors market. Hedgehog pathway is an important signaling pathway for healthy embryonic development. Rising prevalence of chronic target diseases such as cancer, are contributing to the market growth. For instance, every year approximately 17 million new cases of cancer are registered worldwide. Additionally, each year, non-melanoma skin cancer accounts for 2-3 million cases across the globe; wherein one out of every three cancer cases is related to skin cancer. According to the American Brain Tumor Association, approximately 25% of patients in the US are suffering from medulloblastoma due to the uncontrolled Sonic Hedgehog (SHH) pathway. Individuals with medulloblastoma showed a high level of cholesterol when the combination of statin (simvastatin) and Hedgehog pathway inhibitor (vismodegib) was administered to the cohort. The combination therapeutics produces synergistic activity of the inhibitors.
Hedgehog pathway is preferred over other treatment technologies, as it requires a shorter duration of hospital stay and is a painless therapy. Hedgehog inhibitors are either taken orally or applied topically on the affected area, which does not require any special skills or longer duration of hospital stay. This factor is expected to enhance the adaptability of Hedgehog inhibitors. Rising prevalence of cancer, hereditary factors (genetic mutation), new product launches, increasing demand for painless or minimally invasive treatment, and increased resistance to existing treatments, and rising number of market entrants, are some of the major factors boosting the market growth. However, the Hedgehog pathway inhibitors have some side effects, which might restrain the market growth.
Top Companies Profiled in the Report Include:
Pfizer Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Limited, Infinity Pharmaceuticals, Max Biopharma Inc, PellePharm Inc., Takeda Pharmaceutical Company Ltd, Mayne Pharma Group Limited, and Bristol-Myers Squibb Company..
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2130
Further key findings from the report suggest
- During 2019-2026, Hedgehog pathway inhibitors market is expected to register a CAGR of 11.4% in the Asia Pacific; followed by North America and Europe, with 10.4% and 9.9% CAGR respectively. High prevalence of chronic target diseases across the globe is the primary factor driving the market during the forecast period across all regions.
- The basal cell carcinoma segment dominates the market with the highest market share in the year 2018. It is estimated to grow at a CAGR of 11.2% during the forecast period to reach the value of USD 235.8 million by 2026, as more patients are suffering from basal cell carcinoma.
- The oral route for administration of the live vaccines segment is forecast to be the fastest growing market segment. Ease of application and efficient dose delivery to achieve desirable results are some of the factors responsible for the market growth.
- Based on type, the smoothened non-canonical pathway type of Hedgehog inhibitors segment dominates the market, holding the largest market share than the other types.
- Asia Pacific is expected to account for a CAGR of 11.4% of the global Hedgehog pathway inhibitors market. Developing nations such as China and India are likely to witness a high growth due to the high prevalence of target diseases, increased globalization and high availability of Contract Research Organization facilities in the region.
- Apart from developments of new molecules, key market players are engaged in exploring the application of the existing old molecules in Hedgehog pathway inhibitor indications, this is expected to deduct the cost of clinical trials and will provide opportunity for the market players. For instance, Mayne Pharma Group Limited took control of SUBA-itraconazole BCCNS program from HedgePath Pharmaceuticals, Inc.
- Slow rate of commercialization, high costs involved in research and development, reluctance toward the adoption of new treatment practices and stringent government regulations are among the key factors likely to hamper growth of the market.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2130
The report has gather vital information about recent mergers and acquisitions, joint ventures, collaborations, partnerships, brand promotions, RD activities, and government and corporate deals, among others through extensive primary and secondary research. The report also offers detailed analysis of each competitor along with their financial standing, global market position, product portfolio, manufacturing and production capacity, and business expansion plans.
The report offers a comprehensive overview of the regional bifurcation of the market with respect to market share, market size, revenue growth, import/export, production and consumption patterns, macro and micro economic growth factors, regulatory framework, investment and funding opportunities, and presence of key players in each region including North America, Asia Pacific, Latin America, Europe, and Middle East Africa. The report offers a country-wise analysis to further discuss the revenue growth and lucrative growth opportunities for the Hedgehog Pathway Inhibitors market in these key regions.
Country-wise regional analysis covers:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East Africa
To know more about the report @ https://www.reportsanddata.com/press-release/global-hedgehog-pathway-inhibitors-market
Additionally, the report consists a detailed analysis of the segmentation of the Hedgehog Pathway Inhibitors market based on product types and end-use/application offered in the Hedgehog Pathway Inhibitors market.
Product Type Outlook (Revenue, USD Million; 2016-2026)
Glasdegib
Vismodegib
Sonidegib
Itraconazole
Oxysterol
Saridegib
Pathway Type Outlook (Revenue, USD Million; 2016-2026)
Canonical Hedgehog Signaling
Non-Canonical Hedgehog Signaling
Smoothened dependent Non-Canonical
Smoothened independent Non-Canonical
Application Outlook (Revenue, USD Million; 2016-2026)
Basal Cell Carcinoma
Acute Myeloid Leukemia
Medulloblastoma
Gorlin Syndrome
Others
Route of Administration Outlook (Revenue, USD Million; 2016-2026)
Oral
Topical
Patient Use Outlook (Revenue, USD Million; 2016-2026)
Adult
Children
Read More Reports
Vitamin A Market @ https://www.medgadget.com/2021/10/vitamin-a-market-growth-driven-by-growing-prevalence-of-vitamin-deficiency-across-the-globe-reports-and-data.html
Medical Device Security Market @ https://www.medgadget.com/2021/10/medical-device-security-market-growth-driven-by-rising-need-for-medical-device-security-in-the-healthcare-sector-reports-and-data.html
Personal Protective Equipment (PPE) Market @ https://www.medgadget.com/2021/10/personal-protective-equipment-ppe-market-growth-driven-by-rapid-spread-of-covid-19-across-the-globe-reports-and-data.html
Thank you for reading our report. For customization inquiry or further information, please connect with us and we will ensure you get the report that meets your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
